# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 22, 2017

# INTERNATIONAL STEM CELL CORPORATION

(Exact name of registrant as specified in its charter)

**Delaware**(State or other jurisdiction of incorporation)

000-51891

(Commission File Number)

20-4494098

(IRS Employer Identification Number)

5950 Priestly Drive, Carlsbad, California 92008

(Address of principal executive offices, including zip code)

(760) 940-6383

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |  |  |
|---|--|--|
|   | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)                  |  |
|   | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)                 |  |
|   | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)  |  |
|   | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c)) |  |
|   |  |  |
|   |  |  |
|   |  |  |

## Item 1.01 Entry into a Material Definitive Agreement.

| On February 22, 2017, International Stem Cell Corporation entered into an amendment to its existing facilities lease with S Real Estate Holding LL   | .C (  |
|--|-------|
| affiliate of our CEO and EVP, CSO). The amendment extended the term of the lease for three (3) years (until February 29, 2020). The base rent during | ng tł |
| period of March 1, 2017 and February 29, 2020, inclusive, shall increase by 3% each year.  |       |
|  |       |

#### Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 28, 2017

### INTERNATIONAL STEM CELL CORPORATION

By: /s/ Mahnaz Ebrahimi

Mahnaz Ebrahimi Chief Financial Officer